
1 February 2021
All local recommended safety guidelines followed at the time of interview.
When the COVID-19 pandemic descended in Northwest Indiana, USA, Great Lakes Labs president and CEO Michelle Volk redirected her lab’s focus from forensics to clinical medicine to provide her community with rapid, accurate testing, and peace of mind.
icon-cta-blockquote2
I just kept thinking: What can we do? What can Great Lakes Labs do? We don't do clinical testing.
Michelle Volk, CEO and President of Great Lakes Labs
icon-cta-blockquote2
What we were seeing with the testing across the country and monitoring is that it was taking days, up to weeks, for a result to be returned to the clinician.
Michelle Volk, CEO and President of Great Lakes Labs
icon-cta-blockquote2
It was a very easy decision once we learned how sensitive and specific the QIAstat-Dx is and how easy it is to use.
Michelle Volk, CEO and President of Great Lakes Labs
In need of accurate and timely clinical insights for your patients?
QIAstat-Dx is changing the landscape of syndromic testing.
Other stories
-
Deciphering RNA to solve impossible crime scenesForensic scientists at the Netherlands Forensic Institute bring clarity to the chaos of intricate crime scenes by deciphering RNA.
-
Latest information on SARS-CoV-2Find all resources covering diagnostic testing, research solutions and latest news in one place.
-
Our customer StoriesExplore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances.
*Product availability may differ from country to country based on regulations and approvals. Contact your country representative for further details.